Abstract:Our appreciation of mitochondrial disease, in the context of both genetic and phenotypic heterogeneity, has blossomed over recent years with successive epidemiological studies, accrued clinical expertise and scientific advances. Epidemiological studies have encountered numerous obstacles, most importantly the initial recognition and diagnosis of a rare and variable multisystem disorder, but also complex referral pathways, specific and evolving diagnostic techniques, impaired penetrance and heteroplasmic mtDNA mutations, and the potential for ascertainment bias in disease cohorts. These inherent difficulties have contributed to both historical over- and under-representation of specific mtDNA or nuclear DNA-related mitochondrial disease. The last three decades have seen over 250 pathogenic mtDNA mutations identified, and the evolution of whole-genome sequencing is now identifying increasing numbers of pathogenic nuclear disease genes. Only recently has it been possible to estimate the prevalence of disease due to mutations of both the nuclear and mitochondrial genomes. To date, the most detailed prevalence figures available report the number of adults suffering from all forms of mitochondrial disease to be in the region of 12.5 per 100,000 of the population. One in 4300 people (23 per 100,000) carry pathogenic mutations of either nuclear or mtDNA and either have disease or are at risk of disease in the future. The most prevalent single mutation to cause mitochondrial disease is now recognised to be due to the m.3243A>G mutation in the MT-TL1 gene with a disease estimation of 3.5 per 100,000. Childhood-onset mitochondrial disease has been predicted to range from 0.5 to 1.5 cases per 100,000, approximately one-tenth of that seen in adults. Although no true population-based prevalence studies have yet been performed using laborious whole-genome sequencing, most existing studies focus on screening for individual mutations within cohorts felt to represent either the general population or the particular disease-defined cohorts. A small number of specific mtDNA mutations have been identified as causing a proportion of disease in diabetes, deafness and optic neuropathy cohorts. Although often considered a hallmark of mitochondrial disease, the prevalence of diabetes in most forms of mitochondrial disease is no higher than 10–12% as compared with a prevalence in the general population of 4.5%. The recognised association can be mainly attributed to the prevalent m.3243A>G mutation which frequently presents with maternally inherited deafness and diabetes. Deafness is common among many mtDNA mutations, usually as part of a broader phenotype, but can be the sole manifestation in the m.1555A>G mutation, particularly following exposure to aminoglycoside antibiotics. Leber’s hereditary optic neuropathy (LHON) occurs as a result of three common mutations in 90% of affected patients, with the point prevalence of disease standing at 3.7 per 100,000.The provision and development of highly specialised services, prospective cohort studies and use of objective clinical rating scales have contributed heavily to our understanding of the mitochondrial disorders today, and are likely to be instrumental in achieving more accurate epidemiological studies in mitochondrial disease in the future.

Epidemiology of Mitochondrial Disease

Research Progress of Diabetes Induced by Mitochondrial DNA Mutations

[The Influence of Mitochondrial Haplogroup on Leber's Hereditary Optic Neuropathy].

[Modifier Factors Influencing the Phenotypic Manifestation of the Deafness Associated Mitochondrial DNA Mutations].

The Novel A4435g Mutation In The Mitochondrial Trnamet May Modulate The Phenotypic Expression Of The Lhon-Associated Nd4 G11778a Mutation

Frequency and spectrum of MT-TT variants associated with Leber’s hereditary optic neuropathy in a Chinese cohort of subjects

Forecasting stroke-like episodes and outcomes in mitochondrial disease

Diagnostic challenges of mitochondrial DNA disorders

MT-ND5 Mutation Exhibits Highly Variable Neurological Manifestations at Low Mutant Load.

Genetics of mitochondrial diseases: Current approaches for the molecular diagnosis

Mitochondrial diseases in adults

The clinical and genetic spectrum of mitochondrial diseases in China: A multicenter retrospective cross-sectional study

Known genes, new genes and new phenotypes in mitochondrial eye diseases

A Review over Mitochondrial Diseases Due to mtDNA Mutations: Recent Advances and Remedial Aspects

Contribution of nuclear and mitochondrial gene mutations in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome

Mitochondrial molecular genetics and human disease

Benign or pathogenic: Using computer based algorithms for POLG mutation prediction

Genetic basis of mitochondrial diseases

Mutations in Mitochondrially Encoded Complex I Enzyme As the Second Common Cause in a Cohort of Chinese Patients with Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke-Like Episodes

Mitochondrial Russian doll genes may explain some discrepancies in links between mtDNA mutations and mitochondrial diseases

Mutations of the mitochondrial genome: clinical overview and possible pathophysiology of cell damage